MaxCyte (NASDAQ:MXCT) specializes in cell engineering, providing essential tools and technologies that support the development and commercialization of cellular therapies and biotherapeutics. The company's cutting-edge Flow Electroporation technology and instruments facilitate the discovery, development, and manufacture of new therapies, particularly in the field of immune-oncology, cell therapy, and gene editing. MaxCyte aims to accelerate the fight against a wide range of diseases, including cancer, inherited diseases, and infectious diseases, by empowering researchers and pharmaceutical companies to unlock the full potential of their cell-based research. Serving a global clientele, MaxCyte is committed to innovation and excellence in supporting the advancement of science and medicine.